Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHranceSCa: SC vs IV Pertuzumab and Trastuzumab in Early Breast Cancer
NCT03674112Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by Roche. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03674112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674112.